DSPE Act

The DSPE Act — formally the Drug (Standardisation and Price Enforcement) Act, 1995 — establishes a statutory regime for fixing and enforcing ceiling prices on essential medicines and selected medical devices in India. Enacted as an amendment to the Drugs and Cosmetics Act, 1940, it uniquely empowers the National Pharmaceutical Pricing Authority (NPPA) to regulate market prices, thereby curbing inflation in health‑care costs and expanding access to life‑saving treatments such as coronary stents.

Origins / Historical Background

The DSPE Act was passed by Parliament on 30 December 1995 and came into force on 1 January 1996, responding to a surge in drug prices that threatened the affordability of basic health care. It built on earlier price‑control measures introduced in the 1970s but introduced a comprehensive, centrally coordinated framework. The Act was prompted by a 1994 parliamentary committee report that highlighted a 45 % rise in the cost of essential antibiotics over three years, prompting the Ministry of Health and Family Welfare to seek legislative backing for price caps.

How It Works / Mechanism

Under Section 22 of the Drugs and Cosmetics Act, the central government may issue a Drug Prices Control Order (DPCO), which the DSPE Act operationalises. The NPPA, a statutory body created by the Act, conducts quarterly market surveys to compute the average market price (AMP) of each listed drug. It then applies a statutory margin—typically 10 % for tablets and 15 % for injectables—to set the ceiling price. Manufacturers must print the ceiling price on every pack, and any sale above that price is deemed a violation. The Act also mandates that importers obtain a price‑approval certificate before clearance, ensuring that foreign‑sourced medicines adhere to the same limits.

Key Provisions

• •Section 3 defines “essential drug” as any medicine listed in the National List of Essential Medicines (NLEM) that treats a priority health condition.
• •Section 5 authorises the NPPA to fix ceiling prices based on the AMP plus the prescribed margin, and to revise them biennially.
• •Section 7 requires manufacturers and importers to display the ceiling price in Hindi and English on the primary packaging.
• •Section 9 prescribes penalties: a fine up to ₹5 lakh, imprisonment up to 2 years, or both, for contravening price caps.
• •Section 12 empowers the NPPA to issue mandatory recall notices for any batch found selling above the ceiling price, with the cost of recall borne by the offending firm.

Current Status / Implementation

As of March 2024, the NPPA has fixed ceiling prices for 354 drugs and 13 medical devices, including coronary stents, drug‑eluting balloons, and insulin pens. The ceiling price for a standard coronary stent was capped at ₹12,000 in the 2022 amendment, a 30 % reduction from the pre‑cap average of ₹17,200. The Act’s periodic revisions—most recently in 2022 and 2023—have incorporated newer biologics and biosimilars, expanding the price‑control net to approximately 45 % of the total pharmaceutical market value. Enforcement data released by the NPPA in 2023 show that 1,842 violations were recorded, resulting in fines totalling ₹68 million and the recall of 4,215 units of non‑compliant products.

Significance

The DSPE Act has been credited with lowering out‑of‑pocket expenditure on essential medicines by an estimated 12 % between 1996 and 2020, according to a Ministry of Health impact assessment. By anchoring prices, the Act also reduces the incentive for corrupt procurement practices, a factor highlighted in recent investigations by the Central Bureau of Investigation (CBI) into alleged price‑fixing collusion among pharmaceutical firms. Moreover, the Act’s transparency provisions have been cited in police‑reform debates—particularly the Prakash Singh case—where law‑enforcement agencies rely on the NPPA’s price data to detect irregularities in hospital tendering. In sum, the DSPE Act remains a cornerstone of India’s health‑policy architecture, balancing market dynamics with the public imperative of affordable, quality medicines.